Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11959424 | 0.94 | SCNN1A (0.54) | SCNN1AKCNH2 | |
| SCHEMBL12379799 | 0.94 | SCNN1A (0.54) | SCNN1AKCNH2 | |
| Trifluoroacetic Acid SCHEMBL1428387 | 0.91 | SCNN1A (0.46) | SCNN1AKCNH2 | |
| Trifluoroacetic Acid SCHEMBL2288758 | 0.89 | SCNN1A (0.53) | SCNN1AKCNH2 | |
| Trifluoroacetic Acid SCHEMBL1431125 | 0.89 | SCNN1A (0.53) | SCNN1AKCNH2 | |
| Trifluoroacetic Acid SCHEMBL2288753 | 0.89 | SCNN1A (0.53) | SCNN1AKCNH2 | |
| SCHEMBL11959468 | 0.86 | SCNN1A (0.51) | SCNN1AKCNH2 | |
| SCHEMBL11959470 | 0.85 | SCNN1A (0.43) | SCNN1AKCNH2 | |
| SCHEMBL11959421 | 0.85 | SCNN1A (0.51) | SCNN1AKCNH2 | |
| Trifluoroacetic Acid SCHEMBL2291212 | 0.84 | SCNN1A (0.52) | SCNN1AKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2300010-B1 | PYRAZINE DERIVATIVES AS EPITHELIAL SODIUM CHANNEL BLOCKERS | NOVARTIS AG (CH) | 2015-03-04 | — | — | EP | disclosed |
| US-8236808-B2 | Pyrazine derivatives as ENAC blockers | NOVARTIS AG (CH) | 2012-08-07 | — | — | US | disclosed |
| US-20110201625-A1 | Organic Comopunds | NOVARTIS AG (CH) | 2011-08-18 | — | — | US | disclosed |
| EP-2300010-A2 | ORGANIC COMPOUNDS | Novartis AG (CH) | 2011-03-30 | — | — | EP | disclosed |
| WO-2009150137-A2 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2009-12-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110201625-A1 | Organic Comopunds | OR10J3, CFTR, CLIC1 | SCNN1A 52/4885KCNH2 49/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.